Atlas Venture Life Science Advisors, LLC Q4 2024 Filing
Filed February 6, 2025
Portfolio Value
$819.7B
Holdings
13
Report Date
Q4 2024
Filing Type
13F-HR
All Holdings (13 positions)
| Stock | Value |
|---|---|
KYMRKymera Therapeutics, Inc. | $197.0B |
DYNDyne Therapeutics, Inc. | $188.9B |
IRONDisc Medicine, Inc. | $159.1B |
THRDThird Harmonic Bio, Inc. | $107.0B |
DAWNDay One Biopharmaceuticals, Inc. | $81.5B |
KRROKorro Bio, Inc. | $43.3B |
VIGLVigil Neuroscience, Inc. | $9.9B |
GBIOGBXGeneration Bio, Co. | $8.8B |
—Ikena Oncology, Inc. | $8.2B |
QTTBQ32 Bio, Inc. | $7.2B |
AVTEAerovate Therapeutics, Inc. | $4.8B |
TECXTectonic Therapeutics, Inc. | $3.6B |
SPROSpero Therapeutics, Inc. | $314.4M |